References
- Dick A P, Grayson M J, Carpenter R G, Petrie A. Gut 1964; 5: 437–442
- Dissanayake A S, Truelove SC. Gut 1973; 14: 923–926
- Das K M, Eastwood M A, McManus J PA, Sircus W. N Eng J Med 1973; 289: 491–495
- Kirsner J B, Goodman MJ. The medical treatment of inflammatory bowel disease. Inflammatory bowel disease2nd edition., J B Kirsner, R G Shorter. Lea and Febiger, Philadelphia 1980; 413–446
- Taffet S L, Das KM. Dig Dis Sci 1983; 28: 833–842
- Nielsen OH. Scand J Gastroenterol 1982; 17: 389–393
- Azad Khan A K, Howes D T, Piris J, Truelove SC. Gut 1980; 21: 232–240
- van Hees P AM. Clinical and pharmacological aspects of sulphasalazine. MD Thesis, Catholic University of Nijmegen, Holland 1979
- Azad Khan A K, Piris J, Truelove SC. Lancet 1977; ii: 892–895
- van Hees P AM, van Tongeren J HM, Bakker J H, van Leir H JJ. Lancet 1978; i: 277
- Willoughby C P, Aronson J K, Agback H, Bodin N O, Truelove SC. Gut 1982; 23: 1081–1087
- Lauritsen K, Hansen J, Ryde M, Rask-Madsen J. Gastroenterology 1984; 86: 1496–1500
- Truelove S C, Richards W CD. Br Med J 1956; 1: 1315–1318
- Gaurino RA. Drug Cosmetic Industry 1976; 118: 46–47
- Sandberg-Gertzén H, Järnerot G, Kraas W. Gastroenterology 1986; 90: 1024–1030
- Mohsen A QM, Mulvey D, Priddle J, Parsons D S, Jewell DP. Gut 1987; 28: 346–352
- Selby W S, Barr G D, Ireland A, Mason C H, Jewell DP. Br Med J 1985; 291: 1373–1375